Journal ArticleDOI
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients.
Naoual Bakrin,J.M. Bereder,Evelyne Decullier,Jean-Marc Classe,Simon Msika,Gérard Lorimier,Karine Abboud,Pierre Meeus,Gwenael Ferron,François Quenet,Frédéric Marchal,Sebastien Gouy,Philippe Morice,Christophe Pomel,Marc Pocard,Frédéric Guyon,Jack Porcheron,Olivier Glehen +17 more
Reads0
Chats0
TLDR
For advanced and recurrent EOC, curative therapeutic approach combining optimal CRS and HIPEC should be considered as it may achieve long-term survival in patients with a severe prognosis disease, even in patientsWith chemoresistant disease.Abstract:
Background Despite a high response rate to front-line therapy, prognosis of epithelial ovarian carcinoma (EOC) remains poor. Approaches that combine Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have been developed recently. The purpose of this study was to assess early and long-term survival in patients treated with this strategy. Patients and methods A retrospective cohort multicentric study from French centres was performed. All consecutive patients with advanced and recurrent EOC treated with CRS and HIPEC were included. Results The study included 566 patients from 13 centres who underwent 607 procedures between 1991 and 2010. There were 92 patients with advanced EOC (first-line treatment), and 474 patients with recurrent EOC. A complete cytoreductive surgery was performed in 74.9% of patients. Mortality and grades 3 to 4 morbidity rates were 0.8% and 31.3%, respectively. The median overall survivals were 35.4 months and 45.7 months for advanced and recurrent EOC, respectively. There was no significant difference in overall survival between patients with chemosensitive and with chemoresistant recurrence. Peritoneal Cancer Index (PCI) that evaluated disease extent was the strongest independent prognostic factor for overall and disease-free survival in all groups. Conclusion For advanced and recurrent EOC, curative therapeutic approach combining optimal CRS and HIPEC should be considered as it may achieve long-term survival in patients with a severe prognosis disease, even in patients with chemoresistant disease. PCI should be used for patient's selection.read more
Citations
More filters
Journal ArticleDOI
Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update
Gregg Nelson,Jamie N. Bakkum-Gamez,Eleftheria Kalogera,Gretchen E. Glaser,Alon D. Altman,Larissa A. Meyer,Jolyn S. Taylor,Maria D. Iniesta,Javier Lasala,Gabriel E. Mena,Michael J. Scott,Chelsia Gillis,Kevin M. Elias,Lena Wijk,Jeffrey Huang,Jonas Nygren,Olle Ljungqvist,Pedro T. Ramirez,Sean C. Dowdy +18 more
TL;DR: This is the first updated Enhanced Recovery After Surgery (ERAS) Society guideline presenting a consensus for optimal perioperative care in gynecologic/oncology surgery, and the updated evidence base and recommendation are presented.
Journal ArticleDOI
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
TL;DR: The use of hyperthermic intraperitoneal chemotherapy along with the extent of the disease andThe extent of cytoreduction play an important role in the survival of patients with recurrence in an initially advanced ovarian cancer.
Journal ArticleDOI
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
TL;DR: The addition of HIPEC to CRS and chemotherapy improves overall survival rates for both primary and recurrent EOC.
Journal ArticleDOI
What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures
Guillaume Passot,Delphine Vaudoyer,Laurent Villeneuve,Vahan Kepenekian,Annie Claude Beaujard,Naoual Bakrin,Eddy Cotte,François Noël Gilly,Olivier Glehen +8 more
TL;DR: To review the 25‐year experience with hyperthermic intra‐peritoneal chemotherapy (HIPEC), the authors suggest that conventional chemotherapy should be considered as a best method to treat central giant cell granuloma.
Journal ArticleDOI
Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum.
TL;DR: Current data regarding the molecular mechanisms underlying the development of colorectal PC are reviewed, with a special focus on the peritoneum and the role of the surgeon in peritoneal disease spread.
References
More filters
Journal ArticleDOI
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Deborah K. Armstrong,Brian N. Bundy,Lari Wenzel,Helen Q. Huang,Rebecca N. Baergen,Shashikant Lele,Larry J. Copeland,Joan L. Walker,Robert A. Burger +8 more
TL;DR: Quality of life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment, while survival in patients with optimally debulked stage III ovarian cancer improved.
Journal ArticleDOI
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
TL;DR: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables.
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Book ChapterDOI
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis
TL;DR: Objective response criteria from CT scan, tumor marker, and radiolabeled monoclonal antibody studies are necessary in a regular follow-up schedule.
Journal ArticleDOI
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
David S. Alberts,P. Y. Liu,Edward V. Hannigan,Robert V. O'Toole,Stephen D. Williams,Stephen D. Williams,James A. Young,Ernest W. Franklin,Daniel L. Clarke-Pearson,Vinay K. Malviya,Brent DuBeshter,Brent DuBeshter,Mark D. Adelson,William J. Hoskins +13 more
TL;DR: Intraperitoneal cisplatin significantly improves survival and has significantly fewer toxic effects in patients with stage III ovarian cancer and residual tumor masses of 2 cm or less.
Related Papers (5)
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Terence C. Chua,B. J. Moran,Paul H. Sugarbaker,Edward A. Levine,Olivier Glehen,François Noël Gilly,Dario Baratti,Marcello Deraco,Dominique Elias,Armando Sardi,Winston Liauw,Tristan D. Yan,P. Barrios,Alberto Gomez Portilla,Ignace H J T de Hingh,Wim Ceelen,Joerg O.W. Pelz,Pompiliu Piso,Santiago González-Moreno,Kurt Van der Speeten,David L. Morris +20 more
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Willemien J. van Driel,Simone N. Koole,Karolina Sikorska,Jules H. Schagen van Leeuwen,Henk W.R. Schreuder,Ralph H. Hermans,Ignace H. J. T. de Hingh,Jacobus van der Velden,Henriette J. G. Arts,Leon F.A.G. Massuger,Arend G. J. Aalbers,Victor J. Verwaal,Jacobien M. Kieffer,Koen Van de Vijver,Harm van Tinteren,Neil K. Aaronson,Gabe S. Sonke +16 more